Prognostic miRNA-based test for left ventricular remodelling after acute myocardial infarction.
The consortium will develop an innovative diagnostic test to assess the risk of post-acute myocardial infarction (AMI) patients to develop life threatening heart failure (HF). A recently discovered prognostic set of 4 miRNAs will be validated and strengthened for use in a clinical test. Together with clinical information from the patient, the miRNA test will be developed into a new prognostic model for the identification of patients at risk to allow early treatment an monitor treatment response.
1 756 980.00€
Diagnostic test products and equipment